By Vishwadha Chander June 24 (Reuters) - An observational study of Amgen Inc's new osteoporosis drug Evenity released on Wednesday appears to confirm the increased risk of serious heart problems detected in clinical trials and included in the medicine's prescribing information.There has been uncertainty if the cardiovascular risks seen in romosozumab clinical trials were real, study author Jonas Bovijn from the University of Oxford's Big Data Institute told Reuters.